13价肺炎球菌结合疫苗对老年人疫苗型侵袭性肺炎球菌病的有效性
在KPNC≥65岁成人中开展的观察性研究显示,2014年9月1日至2020年12月31日期间,PCV13对PCV13血清型IPD的调整VE为61.5%(95%CI:36.2,76.7;p<0.001),对血清型3 IPD的调整VE为46.3%(95%CI:-2.4,77.9;p=0.06)。研究结论认为PCV13可保护≥65岁成人免受PCV13血清型IPD,持续监测对评估高价PCV影响至关重要。
要点
- PCV13对PCV13血清型IPD的调整VE为61.5%(95%CI:36.2,76.7;p<0.001)。
- PCV13对血清型3 IPD的调整VE为46.3%(95%CI:-2.4,77.9;p=0.06)。
- 研究期间307例IPD中98例(31.9%)为血清型3。
核心结论
- PCV13接种可保护≥65岁成人免受PCV13血清型IPD。
- 持续监测对≥65岁人群评估高价PCV对IPD血清型分布(包括血清型3等单个血清型)的影响至关重要。
研究设计与样本
- 观察性研究,纳入2014年9月1日至2020年12月31日期间KPNC≥65岁成人。
- 研究人群共610,576名≥65岁成人。
- 采用主动实验室监测识别并血清分型所有来自正常无菌部位的肺炎链球菌分离株。
- 采用按年龄和日历日分层的条件logistic回归估计疫苗型IPD的OR,并调整性别、年龄、种族、族裔、流感疫苗接种、65岁后23价肺炎球菌多糖疫苗接种、肺炎危险因素、医疗利用和KPNC服务区域。
- 调整VE计算公式为(1-调整OR)×100%。
主要发现
- 研究期间共307例IPD,其中98例(31.9%)为血清型3。
- PCV13对PCV13血清型IPD的调整VE为61.5%(95%CI:36.2,76.7;p<0.001)。
- PCV13对血清型3 IPD的调整VE为46.3%(95%CI:-2.4,77.9;p=0.06)。
- 研究期末PCV13覆盖率接近80%。
关键数值与推荐
- 2014年,免疫实践咨询委员会推荐≥65岁成人常规使用PCV13。
- PCV13对PCV13血清型IPD的调整VE为61.5%(95%CI:36.2,76.7;p<0.001)。
- PCV13对血清型3 IPD的调整VE为46.3%(95%CI:-2.4,77.9;p=0.06)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2014, the Advisory Committee on Immunization Practices recommended routine use of the 13-valent pneumococcal conjugate vaccine (PCV13) in adults age ≥ 65 years. Incidence of most PCV13-serotype cases declined, however serotype 3 cases have persisted. We estimated PCV13 vaccine effectiveness (VE) against PCV13-serotypes and serotype 3 invasive pneumococcal disease (IPD) among Kaiser Permanente Northern California (KPNC) adults. METHODS: This observational study included adults ≥65 years between September 1, 2014-December 31, 2020. We used active laboratory-based surveillance to identify and serotype all Streptococcus pneumoniae isolates obtained from normally-sterile sites. We estimated the odds ratio (OR) of vaccine-type IPD using conditional logistic regression stratified by age and calendar day, adjusting for sex, age, race, ethnicity, influenza vaccine receipt, 23-valent pneumococcal polysaccharide vaccine receipt since age 65, pneumonia risk factors, healthcare utilization, and KPNC service area. We estimated VEAdjusted as (1-ORAdjusted) × 100 %. RESULTS: There were 610,576 adults ≥65 years in the study population. By the end of the study period, PCV13 coverage was nearly 80 %. There were 307 IPD cases during the study period, of which 98 (31.9 %) were serotype 3. PCV13 was associated with a VEAdjusted of 61.5 % (95 % CI: 36.2, 76.7; p < 0.001) against PCV13-serotype IPD and 46.3 % (95 % CI: -2.4, 77.9; p = 0.06) against serotype 3 IPD. CONCLUSIONS: PCV13 vaccination protected adults ≥65 years against IPD due to PCV13 serotypes. Continued surveillance will be critical in the ≥65-year-old population to assess the impact of higher valent PCVs on IPD serotype distribution, including individual serotypes such as serotype 3.
引用
- Hsiao A, Lewis N, Hansen J, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in older adults. Vaccine. 2024. PMID: 39637487. doi:10.1016/j.vaccine.2024.126543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。